Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Closed vs Open Triple Therapy in COPD
NCT02729051Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2016
- Primary completion
- May 2017
- Modality
- Orthosteric Ligands
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of fluticasone in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Change From Baseline in Trough Forced Expiratory Volume in One Second at 24 weeks. Started Jun 2016; status: completed.
02
Drugs
fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02729051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02729051.